Could a diabetes drug shield your brain from stroke and dementia?

NCT ID NCT05356104

Recruiting now Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a GLP-1 drug, already used for diabetes, can slow down small vessel disease in the brain—a major cause of stroke, dementia, and mobility issues. About 110 adults aged 55 to 80 with moderate-to-severe disease will receive the drug or a placebo. The goal is to see if it can prevent worsening of brain damage and thinking problems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CEREBRAL SMALL VESSEL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cerebral Small Vessel Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CEREBRAL SMALL VESSEL DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Chinese University of Hong Kong
RECRUITING

Hong Kong, Hong Kong

Contact Phone: •••-•••-•••• Email: •••••@•••••
First Affiliated Hospital of Wenzhou Medical University
RECRUITING

Wenzhou, Zhejiang, China

Contact Email: •••••@•••••